Results 41 to 50 of about 4,256 (179)
British Journal of Clinical Pharmacology, EarlyView.Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang +5 more
wiley +1 more source
Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials
Journal of Diabetes, 2019 AbstractSodium glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs that were primarily developed for the treatment of type 2 diabetes mellitus. However, these agents have shown to provide additional beneficial effects. We will discuss three main topics regarding the use of SGLT2 inhibitors: noncardiovascular effects, cardiovascular benefits,
José Silva‐Cardoso +6 more
openaire +2 more sources
Role of selenium in the pathophysiology of cardiorenal anaemia syndrome
ESC Heart Failure, Volume 12, Issue 2, Page 770-780, April 2025.Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) have multiple bidirectional mechanisms, and anaemia is one of the critical factors that are associated with the progression of the two disorders [referred to as cardiorenal anaemia syndrome (CRAS)].
Shigeyuki Arai +2 more
wiley +1 more source
Frontiers in PharmacologyObjectivesThis study systematically assessed the efficacy and safety of 15 incretin-based therapies (IBTs) for type 2 diabetes mellitus (T2DM), including mono- (GLP-1RA), dual- (GIP/GLP-1RA or GLP-1/GCGR), and triple- (GIP/GLP-1/GCGR) receptor agonists ...
Xichao Wu +5 more
doaj +1 more source
The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle
ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley +1 more source
SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
Diseases, 2020 Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of oral hypoglycemic agents which increase urinary glucose excretion by suppressing glucose reabsorption at the proximal tubule in the kidney. SGLT2 inhibitors lower glycated hemoglobin (
Yoshifumi Saisho
doaj +1 more source
The role of SGLT2 inhibitors beyond glucose-lowering to cardio-renal protection
Российский кардиологический журнал, 2021 People with type 2 diabetes mellitus (T2DM) are at high risk of developing cardiovascular disease (CVD) and kidney disease. This enhanced cardio-renal risk persists despite improvements in care and treatments over the last 20 years.
J. Karalliedde
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1194-1202, April 2025.Abstract Aims Cardiac decompensation in cardiorenal syndrome (CRS) results in systemic congestion usually treated with diuretics. When despite high doses of diuretics, response is poor, ultrafiltration (UF) appears to be a useful and safe technique.
Borja Guerrero Cervera +12 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1132-1140, April 2025.Abstract The main purpose of this project was to capture experts' opinion on hyperkalaemia management and form best practice recommendations for cardiorenal patients in Greece. A steering committee of nephrologists and cardiologists developed 37 statements. An online questionnaire completed by 32 experts in cardiorenal management in Greece.
Christina Chrysohoou +3 more
wiley +1 more source
Cardiorenal MedicineBackground: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of agents initially developed for glycemic control in type 2 diabetes mellitus.
Wei Huang +6 more
doaj +1 more source